GILEAD SCIENCES, INC

GILD
Delayed Quote. Delayed  - 08/15 04:00:00 pm
66.21USD +5.16%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).

Number of employees : 14 400 people.
Sales per Business
20202021
Innovative Medicines24 689.00100.2%27 305.0099.8%
USD in Million
Sales per region
20202021
United States18 217.0073.9%19 267.0070.4%
Europe4 135.0016.8%4 874.0017.8%
Other International2 337.009.5%3 164.0011.6%
USD in Million
Managers
Name Title
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Kelly A. Kramer Independent Director
Jacqueline K. Barton Independent Director
Harish M. Manwani Independent Director
Sandra J. Horning Independent Director
Javier J. Rodriguez Independent Director
Shareholders
Name Equities %
The Vanguard Group, Inc. 105,112,593 8.38%
Capital Research & Management Co. 64,780,000 5.16%
SSgA Funds Management, Inc. 57,970,959 4.62%
Capital Research & Management Co. (Global Investors) 55,951,379 4.46%
Capital Research & Management Co. (World Investors) 49,501,852 3.95%
Dodge & Cox 36,966,627 2.95%
BlackRock Fund Advisors 28,233,440 2.25%
Geode Capital Management LLC 23,172,575 1.85%
Arrowstreet Capital LP 18,002,214 1.44%
Northern Trust Investments, Inc.(Investment Management) 15,313,169 1.22%
Company contact information
333 Lakeside Drive
CA 94404 San Mateo, California


Phone : +1 650 574 3000
Fax : +1 650 578 9264
web site : http://www.gilead.com
Markets and indexes
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 100, S&P 500, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  GILD:US
- Reuters Code :  GILD.O
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-17.07%82 985
GILEAD SCIENCES, INC.-8.81%82 985
VERTEX PHARMACEUTICALS39.13%78 356
REGENERON PHARMACEUTICALS, INC.1.86%68 773
WUXI APPTEC CO., LTD.-20.33%40 492
BIONTECH SE-36.97%39 486
GENMAB A/S0.23%24 079
ARGENX SE19.03%21 041
BEIGENE, LTD.-27.23%20 400
NEUROCRINE BIOSCIENCES, INC.26.09%10 271
SAREPTA THERAPEUTICS, INC.21.09%9 548
KARUNA THERAPEUTICS, INC.108.94%9 153
LEGEND BIOTECH CORPORATION0.24%7 609
EXELIXIS, INC.6.13%6 244
ASCENDIS PHARMA A/S-19.97%6 009
HALOZYME THERAPEUTICS, INC.7.16%5 937
PHARMAESSENTIA CORPORATION94.54%5 398
CEREVEL THERAPEUTICS HOLDINGS, INC.6.20%5 363
ARROWHEAD PHARMACEUTICALS, INC.-27.13%5 114
INTRA-CELLULAR THERAPIES, INC.0.36%4 959
MIRATI THERAPEUTICS, INC.-41.15%4 800
Brand Portfolio
CELL DESIGN LABS
CELL DESIGN LABS
EPITHERAPEUTICS
EPITHERAPEUTICS
FORTY SEVEN
FORTY SEVEN
GILEAD SCIENCES
GILEAD SCIENCES
KITE PHARMA
KITE PHARMA
LETAIRIS
LETAIRIS
NIMBUS APOLLO
NIMBUS APOLLO
» More brands of Gilead Sciences, Inc.